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Summary A prospective, dose-escalating, quasi-experimental clinical trial was conducted
with a traditional healer using a decoction of Argemone mexicana for the treatment of malaria
in Mali. The remedy was prescribed in three regimens: once daily for 3 days (Group A; n = 23);
twice daily for 7 days (Group B; n = 40); and four times daily for the ﬁrst 4 days followed by twice
daily for 3 days (Group C; n = 17). Thus, 80 patients were included, of whom 80% were aged
<5 years and 25% were aged <1 year. All presented to the traditional healer with symptoms
of malaria and had a Plasmodium falciparum parasitaemia >2000/l but no signs of severe
malaria. The proportions of adequate clinical response (ACR) at Day 14 were 35%, 73% and
65% in Groups A, B and C, respectively (P = 0.011). At Day 14, overall proportions of ACR were
lower in children aged <1 year (45%) and higher in patients aged >5 years (81%) (P = 0.027). Very
few patients had complete parasite clearance, but at Day 14, 67% of patients with ACR had a
parasitaemia <2000/l. No patient needed referral for severe disease. Only minor side effects
were observed. Further research should determine whether this local resource could represent
a ﬁrst-aid home treatment in remote areas.
opica© 2007 Royal Society of Tr
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alaria mortality and morbidity is increasing in Africa
espite initiatives to control it (Anonymous, 2005). Many
atients rely on traditional herbal medicines as their ﬁrst
ine of treatment, especially in rural areas. However, few
linical studies have been conducted to evaluate their safety
nd efﬁcacy.
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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In Mali, the Department for Traditional Medicine,
within the Ministry of Health, produces standardised
‘improved traditional medicines’ (me´dicaments tradition-
nels ame´liore´s (MTA)), which are included in the National
Formulary (Ministe`re de la Sante´, des Personnes Age´es et
de la Solidarite´, 1998). Currently, a mixture of three herbs
called ‘Malarial’ is marketed as an antimalarial (Diallo et
al., 2004) but it has never been tested in children under the
age of 5 years. This study was undertaken to provide data
that could support the development of a new MTA as well
as ofﬁcial recommendations on the use of local resources in
situations where standard modern drugs are lacking despite
all possible efforts.
An ethnobotanical and retrospective treatment—
outcome clinical study in the Sikasso and Bandiagara
regions of Mali led to the recognition of the widespread
use of plants by local communities in the management of
malaria and identiﬁed a number of plants used (Diallo et al.,
2006). Patients were asked about their recent experience
of clinical outcomes following the use of diverse treat-
ments for malaria, and the plants with the best outcomes
were also tested in vitro at the Swiss Tropical Institute
in Basel. The most effective plant, according both to the
patients and to the in vitro tests, was Argemone mexicana
L (Papaveraceae). The 50% inhibitory concentration (IC50)
values of the aerial parts against the chloroquine-resistant
K1 strain of Plasmodium falciparum were 5.89, 6.22,
1.22 and 1.00g/ml for the aqueous decoction, aqueous
maceration, and dichloromethane and methanol extracts,
respectively.
Argemone mexicana is a pantropical weed originating
from Mexico (Figure 1). It has a long history of use in tradi-
tional medicine, dating back to the Aztecs (Emmart, 1940).
After the plant spread to India, it was used to treat a
wide variety of diseases in Ayurvedic and Unani medicine,
including malaria (Nadkarni, 1976). It is also used as an anti-
malarial in several African countries, including Benin, Mali
and Sudan. Its in vitro efﬁcacy against P. falciparum has been
conﬁrmed by several studies (Adjobimey et al., 2004; Diallo
et al., 2006; Simonsen et al., 2001). No previous clinical
studies have been conducted to determine its safety and
efﬁcacy in human patients.
To our knowledge, this study is unique in herbal
antimalarial research in its focus on young children in sub-
Saharan Africa, the most vulnerable group.
2. Materials and methods
2.1. Setting
This study was conducted in the village of Missidougou, in
the Sikasso region (southwest) of Mali. The village is located
40 km from the nearest Malian primary health centre and
70 km from the nearest hospital, including a 25 km dirt track
along which there is no public transport.
The village chief of Missidougou is a traditional healer
(Figure 1). His grandfather taught him to treat malaria using
A. mexicana and he has already passed this knowledge to his
son. There is therefore the experience of at least four gener-
ations in the use of this plant for the treatment of malaria in
Missidougou. A previous ethnomedical survey found that use
a
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iigure 1 Chief Tiemoko Bengaly holding Argemone mexicana,
he plant his grandfather taught him to use as a treatment for
alaria. ©Merlin L. Willcox.
f this treatment was systematically associated with good
utcomes (Diallo et al., 2006; Graz et al., 2005).
.2. Participants
atients consulting the traditional healer and diagnosed
ith malaria by him were sent for blood ﬁlms and clinical
valuation. Those with a pure P. falciparum parasitaemia
2000/l, with symptoms of malaria within the last 24 h and
ithout any signs of severe disease were asked for their con-
ent to participate. There was an information sheet, which
atients were given to keep for reference and which was
ead and translated to the patients and their parents in the
ocal language, as most were illiterate. Subjects gave indi-
idual written consent, usually with a ﬁngerprint as most
ould not sign their name.
Exclusion criteria included: severe malaria; pregnancy
although subsequent enquiry revealed that A. mexicana is
dministered to pregnant women, with no reported prob-
ems); age <3 months; other concomitant febrile illness;
dministration of a full course of antimalarial (modern or
raditional) within the previous week; lack of consent; and
nability to return for follow-up.
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Those excluded from the study received traditional treat-
ent. Patients whom the traditional healer could not treat
including those with severe malaria) were referred to the
edical team for a consultation, and treated with modern
edicine if appropriate.
.3. Preparation and dosage
rgemone mexicana grows like a weed in villages of the
ikasso region of Mali. The aerial parts are harvested and
ried in the shade. The antimalarial decoction is prepared
y ﬁlling a cooking pot with as much dried plant mate-
ial as possible (approximately 1 kg), ﬁlling it with water
approximately 10 l) and boiling it for 3 h. The decoc-
ion is drunk hot or allowed to cool. It can be kept in
closed container for a few days. Often the traditional
ealer also washes the patient (especially small children)
ith the decoction and the mother sometimes gives the
reparation intrarectally to toddlers, but in the context
f this study these routes of administration were not
nvestigated.
The traditional healer determined the unit dose of the
ecoction, which varied in quantity according to the age of
he patient. The healer prescribed a single dose daily for 3
ays (‘lower range’ regimen) to the ﬁrst 23 patients (Group
). The following cohort of 40 patients (Group B) received
ne dose twice a day for 7 days (the average usual regimen).
ﬁnal group of 17 patients (Group C) were then prescribed
he ‘upper range’ regimen: one dose four times a day for
he ﬁrst 4 days, then one dose twice daily until the eighth
ay.
It is important to emphasise that the dose escalation
as not planned as part of the study design. The tra-
itional healer was asked to determine the dose and at
rst decided to prescribe dose ‘A’. When it became appar-
nt that this was not very effective, the team questioned
im and he explained he thought that this dose was more
scientiﬁc’ (perhaps because it is the same dosage fre-
uency as chloroquine). The team asked what the usual
ose was and he replied that he normally gives the dried
lant to the patients to prepare at home and told them
o drink as much as possible. There had been no standard
requency or duration of treatment. The healer and the
esearch team mutually agreed on dosage schedules ‘B’
nd ‘C’ as a standardisation of average and ‘upper range’
oses.
.4. Design
he study was a prospective, dose-escalating, quasi-
xperimental (since no randomisation was performed to
llocate participants to the treatment groups) clinical trial.
atients were seen on Days 0, 1, 2, 3, 7, 14 and 28, and
ny intermediate day if they became unwell. On each visit,
atients were assessed clinically. Blood ﬁlms were taken on
ll visits except Day 1. A sample of venous blood was taken
n Days 0, 3, 7 and 14 for measurement of haematocrit,
hite cell count, platelet count, liver enzymes (aspartate
minotransferase (AST) and alanine aminotransferase (ALT))
nd creatinine. Haematocrit was also measured on Day 28.
lectrocardiograms (ECG) were taken on Days 0, 3, 7 and 14.
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In cases of treatment failure, patients were given
lternative treatment with standard ﬁrst-line antimalarials
which were chloroquine or sulfadoxine/pyrimethamine at
hat time). No further blood tests were taken after com-
encement of the alternative treatment, unless clinically
ndicated.
.5. Main outcome measures
he outcome measures were those deﬁned by the Research
nitiative for Traditional Antimalarial Methods guidelines for
tudies on traditional antimalarial remedies (Willcox and
lanrewaju, 2004). These are based on WHO (1996) deﬁni-
ions. For this study, ‘fever’ was deﬁned as history of fever
n the previous 24 h, or axillary temperature ≥37.5 ◦C.
Adequate clinical response (ACR) was deﬁned as the
bsence of parasitaemia on Day 14 irrespective of temper-
ture or symptoms, or absence of fever irrespective of the
resence of parasitaemia, without previously meeting any
f the criteria of early or late treatment failure.
Early treatment failure (ETF) was deﬁned as development
f danger signs on Days 1, 2 or 3 in the presence of par-
sitaemia; fever on Day 2 with parasitaemia greater than
t baseline; or fever on Day 3 with parasitaemia. (Afebrile
atients with parasitaemia on Day 3 ≥25% of the count on
ay 0 were not counted as ETF but were observed closely.)
Late treatment failure was deﬁned as development of
ny danger signs or signs of severe malaria in the presence
f parasitaemia on any day from Days 4 to 14, without pre-
iously meeting any of the criteria of ETF; or fever with
arasitaemia on any day from Days 4 to 14, without previ-
usly meeting any of the criteria of ETF.
.6. Laboratory methods
ﬁeld laboratory was installed in one of the village houses,
sing a solar panel and car battery to power microscopes,
entrifuges and an ECG machine. Blood ﬁlms were stained
ith 10% Giemsa for 10min, and parasite counts were done
sing standard WHO criteria. All blood ﬁlms were checked
y two independent microscopists. If there was a difference
100% between the two results, it was repeated by a third
icroscopist until there were two concordant results.
Haematocrit wasmeasured usingmicrohaematocrit tubes
n a centrifuge. White blood cells and platelets were counted
anually using a Malassez chamber. Glucose was measured
n Day 0 using a glucometer (Ascensia Breeze; Bayer Health-
are, Newbury, UK). AST, ALT and creatinine were measured
y the laboratory at Sikasso Hospital. Blood was centrifuged
ithin a few hours of the sample being taken and the serum
as transported to the hospital within 72 h. ECGs were taken
sing a Cardisuny 501 SA single channel electrocardiograph
Fukuda M-E Kogyo Co. Ltd., Tokyo, Japan) and analysed
anually. ECGs and venous blood samples were not rou-
inely taken from children aged <5 years. Blood was also
aken on ﬁlter paper at inclusion and was stored. Patients
ho had a negative blood ﬁlm at Day 14 but parasitaemia
gain by Day 28 had a second ﬁlter-paper blood sample taken
or PCR analysis to determine whether these patients had a
ecrudescence or a re-infection.
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Table 2 Total doses taken by patients over the course of
treatment (ml/kg)
Group A Group B Group C
Mean total dose 12.9 84.6 152.0
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2.7. Statistical analysis
Data were entered and analysed using Epi Info 5.01 (CDC,
Atlanta, GA, USA) and SPSS 11.0 (SPSS Inc., Chicago, IL, USA)
software. Comparison of baseline characteristics of included
patients was performed using Pearson’s 2, Fisher’s exact
test, one-way ANOVA and Kruskal—Wallis non-parametric
ANOVA as appropriate. Comparison of group-speciﬁc results
was assessed using the 2 test for linear trend.
The univariate odds ratio for ACR was calculated with 95%
CI. Subsequently, a multiple logistic regression analysis was
performed, including variables with a level of signiﬁcance of
P < 0.25 in the univariate analysis. Haematocrit, leukocyte
and platelet counts over time were assessed with a multi-
level regression model for repeated measures (Raudenbush,
2001; Raudenbush and Bryk, 2002). The software used was
Hierarchical Linear and Non Linear Modelling (HLM), version
5.0 (Raudenbush et al., 2001).
3. Results
3.1. Patients included
From mid September to mid November 2004, which is the
peak malaria season in the region, 251 patients were diag-
nosed with ‘soumaya’ (malaria) by the traditional healer
and were screened for inclusion in this study. Of these,
167 patients were excluded, with the principal reason
being insufﬁcient parasitaemia (n = 118). Other reasons were
absence of parasites (n = 30), concomitant illness (n = 5) and
miscellaneous (n = 14).
Eighty-four patients were initially included, but three of
these were subsequently excluded because of withdrawal of
consent (n = 2) or discovery of an exclusion criterion (n = 1).
One patient did not fall into any of the three main dosage
groups, so was excluded from the main analysis.3.2. Baseline characteristics
The three dosage groups are comparable in most respects
(see Table 1). However, splenomegaly was signiﬁcantly more
frequent in Group A than in Groups B and C, the initial tem-
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Table 1 Baseline characteristics of patients included in the study
Group A (n = 23)
No. (%) male 12 (52%)
Median age (years) 2.29
Median weight:age ratio (kg/years) 5.0
Splenomegaly present (%) 13 (57%)
Hepatomegaly present (%) 3 (13%)
Mean temperature (◦C) (±SD) 38.4 (±0.7)
Geometric mean parasite count (per l) 19 634
Haematocrit (%) (±SD)d 32.7 (±5.2) [18]
Mean glucose (mmol/l) (±SD)d 5.7 (±1.5) [19]
a Pearson’s 2 or Fisher’s exact test.
b Kruskal—Wallis test.
c One-factor ANOVA.
d Number of patients tested in square brackets.Minimum total dose 6.5 28.1 23.8
Maximum total dose 25.7 162.0 333.0
erature in Group A was higher than in Groups B and C and
he initial parasitaemia was lower in Group B than in Groups
and C. This could be explained by the fact that at the start
f the study, many patients came to be screened (exceeding
he capacity of the research team), therefore it was nec-
ssary to prioritise the patients who had higher measured
emperatures. Very few patients (one in Group A, two in
roup B and none in Group C) had taken any antimalarials
n the preceding week.
.3. Dosage and compliance
lthough not every administration of medicine was
bserved, patients were asked about their compliance with
he prescribed treatment. The reported dose was calcu-
ated for each patient and summarised as a total dose over
he course of treatment (Table 2). There was no overlap
etween Groups A and B, and the dose taken by Group B was
n average 6.5 times greater than the dose taken by Group A.
here was not such a large increase in dose between Groups
and C.
Reported compliance was better in Group A than in
roups B or C; 40% of patients in Group B and 35% of those
n Group C took less than the dose prescribed, but approx-
mately 50% of patients in both groups took more than the
ose prescribed.
.4. Clinical efﬁcacyverall results at Day 14 by intention-to-treat are shown
n Table 3. There is a statistically signiﬁcant difference
etween Group A (35% ACR) and Group B (73% ACR). Groups
Group B (n = 40) Group C (n = 17) P-value
20 (50%) 9 (53%) 0.974a
1.92 2.00 0.944b
5.5 4.75 0.656b
11 (28%) 3 (18%) 0.005a
4 (10%) 1 (6%) 0.115a
37.8 (±1.0) 37.8 (±0.7) 0.024c
14 825 33 884 0.050c
30.6 (±6.5) [35] 27.8 (±5.3) [17] 0.056c
5.6 (±1.3) [33] 6.3 (±1.4) [9] 0.404c
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Table 3 Overall results at Days 14/28 according to treatment group (%)
Group A (n = 23) Group B (n = 40) Group C (n = 17) P-valuea
Adequate clinical response 35/22 73/63 65/59 0.011/0.027
Early treatment failure 26/26 15/15 12/12 0.420
Late treatment failure 35/39 13/23 24/29 0.111/0.372
Lost to follow-up 9/9 0/0 0/0 0.079
a 2 test for linear trend.
Table 4 Percentage of patients with adequate clinical response at Days 14/28, according to age groupa
Age (years) Group A (n = 23) Group B (n = 40) Group C (n = 17) P-valueb Totalc P-valueb
<1 (n = 20) 29/0 [7] 60/50 [10] 33/33 [3] N/A 45/30 0.027/0.12
1—5 (n = 44) 25/17 [12] 71/62 [21] 73/64 [11] 0.019/0.079 59/50
>5 (n = 16) 75/75 [4] 89/78 [9] 67/67 [3] N/A 81/75
a in e
).
B
c
W
d
c
s
d
l
AFigures in square brackets indicate the total number of patients
b 2 test for linear trend (Groups <1 year and >5 years not tested
c Groups A, B and C pooled together.
and C had similar results (73% vs. 65% ACR). These results
an be further broken down by age group (see Table 4).
ithin the age group 1—5 years, there was a very signiﬁcant
ifference in the proportion of ACRs in dose Group A (25%)
ompared with dose Group B (71%). Age- and group-speciﬁc
igniﬁcant differences remain even when adjusting for
ifferences in baseline characteristics, as assessed by a
r
t
a
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Table 5 Univariate and multivariate analyses of adequate clinica
Variable Univariate analysis
OR (95% CI) P-va
Treatment group
A 1 (reference)
B 4.9 (1.6—14.9) 0.00
C 3.4 (0.9—12.8) 0.06
Age group (years)
<1 1 (reference)
1—5 1.9 (0.7—5.5) 0.22
>5 5.8 (1.3—26.5) 0.02
Baseline temperature (◦C)
≥38.5 1 (reference)
38.4—37.5 1.1 (0.4—3.0) 0.89
<37.5 3.4 (0.9—13.6) 0.07
Baseline parasite count (per l)
≥30 000 1 (reference)
29 999—10 000 1.3 (0.4—4.1) 0.61
<10 000 1.1 (0.4—3.3) 0.54
Splenomegaly
Yes 1 (reference)
No 1.2 (0.5—3.0) 0.75
Hepatomegaly
Yes 1 (reference)
No 0.9 (0.2—3.9) 0.85
OR: odds ratio; AOR: adjusted odds ratio.ach group.
ogistic regression model (see Table 5). Of the patients with
CR at Day 14, 56%, 86% and 91% in Groups A, B and C,
espectively, still had an ACR by Day 28.
The age groups <1 year and >5 years were too small
o be able to detect any differences within these groups
ccording to the dosage. However, patients aged <1 year
ere almost half as likely to have an ACR compared with
l response at day 14
Multiple logistic regression
lue AOR (95% CI) P-value
1 (reference)
5 4.5 (1.3—15.2) 0.016
5 3.1 (0.7—13.1) 0.130
1 (reference)
2 1.7 (0.5—5.5) 0.366
4 5.1 (1.0—26.4) 0.055
1 (reference)
9 1.0 (0.3—3.1) 0.981
8 1.5 (0.3—7.2) 0.604
0
6
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shown to be the alkaloid sanguinarine (Sarkar, 1948). How-
ever, using HPLC and mass spectrometry analysis we were
unable to detect sanguinarine in the herbal tea prepared
from A. mexicana in Mali. Experiments have proven that
sanguinarine is nearly exclusively located in the seeds of
A. mexicana (A. Diop, K. Hostettmann’s group, University of
Geneva, Switzerland, personal communication). Even pure
crushed seeds boiled for 3 h in water produced an aqueous
phase devoid of sanguinarine, probably because this com-
pound is destroyed by such treatment or because it is not
extracted by water under these conditions.
Acute toxicity testing of this tea in mice showed no evi-
dence of any adverse effects at doses up to 3.2 g/kg of the
freeze-dried tea, equivalent to 35 g/kg of the plant powder
(Sidibe, 2006).
Patients were asked about any new symptoms they were
experiencing and these were assumed to be adverse effects
of the medication, although it is possible that they had
other causes. Cough and diarrhoea were the commonest
‘adverse events’ and were reported in 17—25% of patients in
each group. All of these were graded as mild or moderate.
There were no severe adverse events, and no patient had to
stop treatment because of an adverse event. These adverse
events were not correlated with a higher dose of treatment.
Among available blood tests, multilevel regression mod-
els showed an overall signiﬁcant increase in haematocrit
between Day 0 and Day 28 in Group C (P = 0.001) but not
in Groups A (P = 0.570) or B (P = 0.069) (Figure 3). No signiﬁ-
cant difference was observed in the progression of white cell
counts. The platelet counts increased signiﬁcantly between
Days 0 and 14 in Groups B (P = 0.043) and C (P < 0.001); noFigure 2 Parasitaemia in all patients during treatment with
Argemone mexicana.
those aged >5 years (45% vs. 81%; P = 0.027) (Table 4).
Overall ACR gave comparable results when adjusted for
age and baseline temperature. Baseline parasite count,
splenomegaly and hepatomegaly were not signiﬁcantly
associated with ACR at day 14 (Table 5).
Of the patients with treatment failure, only one showed
some signs compatible with severe malaria: a history of
repeated convulsions and hyperparasitaemia. The patient
was conscious and able to drink when reviewed, so was
treated with oral artemether/lumefantrine (Coartem®) and
made a good, uncomplicated recovery. All the other treat-
ment failures were patients with persistent fever and
parasitaemia despite treatment, but had no danger signs.
3.5. Parasitological efﬁcacy
Figure 2 shows the change in parasitaemia in the course of
treatment in all patients (parasitaemia was no longer mea-
sured after commencement of a conventional antimalarial).
The majority of patients with ACR at Day 14 still had a mea-
surable parasitaemia, albeit at a lower level than at the
start of treatment. Of these patients, the parasitaemia was
<2000/l (the minimum parasitaemia needed for inclusion in
this study) in 88% of those in Group A, 59% in Group B and 73%
in Group C (overall 67%). Only four patients in Group B (14%
of ACRs) and three in Group C (27% of ACRs) had complete
parasite clearance at Day 14. Of these, ﬁve had measurable
parasitaemia again at Day 28. PCR was only obtainable for
one of these patients and suggested a recrudescence.
3.6. Safety
Several studies have documented the toxicity of the oil
obtained from A. mexicana seeds. These are similar in
appearance to mustard seeds and sometimes their oil has
been found as a contaminant in mustard oil used for cooking,
resulting in ‘epidemic dropsy’ in those inadvertently con-
suming it (Tandon et al., 1975). The toxic constituent was
Figure 3 Change in average haematocrit (%) and platelet
counts stratiﬁed by treatment group in patients receiving Arge-
mone mexicana decoction (haematocrit: n = 74 on Day 0, n = 43
on Day 14 and n = 27 on Day 28; platelets: n = 55 on Day 0, n = 44
on Day 7 and n = 34 on Day 14). aStatistical signiﬁcance of slope.
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igniﬁcant trend was observed in Group A (P = 0.420)
Figure 3). Increases in haematocrit and platelet counts
owards normal levels are expected with successful treat-
ent. There was no evidence of bone marrow toxicity at
he doses given.
Twenty-four of the included patients had at least three
esults for biochemical parameters. There were no signiﬁ-
ant differences in creatinine between Day 0 and subsequent
ays, except in two patients who had an elevated creatinine
t Day 0, which returned to normal on subsequent tests.
even patients (mainly in Group B) had a mild transient ele-
ation of AST and/or ALT at Days 3 or 7, which returned to
ormal by Day 28.
Thirteen patients had ECGs recorded. Signiﬁcant ECG
hanges were only seen in two patients in Group C, one of
hom had taken more than the prescribed dose. They devel-
ped corrected QT intervals >500ms on Day 3, returning to
ormal by Days 7—14. This was accompanied by ﬂattening
f the T waves and appearance of U waves. Testing of the
tored serum samples for these patients revealed that their
otassium levels were normal, so these changes are pre-
umed to be a direct effect of the herbal remedy at high
ose.
. Discussion
.1. Statement of principal ﬁndings
he decoction of A. mexicana used in this study appears
o be effective for the treatment of uncomplicated malaria
hen taken for at least 7 days with two doses a day (Group
). Patients taking this dose had signiﬁcantly better clini-
al results than those taking only one dose daily for 3 days
Group A). There appeared to be no advantage in taking the
ecoction four times a day for the ﬁrst few days (Group C),
nd this dosage was associated with an increased risk of car-
iac toxicity, as evidenced by QT prolongation seen in the
CGs of two patients.
These overall results must be interpreted in the con-
ext of the patient’s age. Patients aged <1 year had poor
esults, possibly because young children often refused to
rink an adequate quantity of the decoction and did not
eceive the preparation by other recommended routes
uch as washing. Furthermore, immunity to malaria is
ot well developed in this age group. In those aged 1—5
ears, there was a very signiﬁcant difference between
roup A and Group B (25% vs. 71% ACR at Day 14), sug-
esting that this is the age group where the treatment
an make the biggest potential difference in outcome.
atients aged >5 years tended to have a good out-
ome, presumably because of a better developed immune
esponse.
.2. Strengths and weaknesses of the study
his study was not randomised, therefore confounding fac-
ors could play some part in the differences between groups.
he temperature threshold for Group A was higher than for
ubsequent groups. However, signiﬁcant differences remain
ven when adjusting for differences in baseline character-
stics such as parasite count, splenomegaly or temperature.
E
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here were insufﬁcient numbers of patients in the groups
ged <1 year and >5 years to be able to determine any effect
f dosage in these groups. The decoction of A. mexicana was
repared by the traditional healer and there was no stan-
ardisation, so there could have been variations between
atches.
.3. Strengths and weaknesses in relation to other
tudies, discussing important differences in results
his is one of the larger cohort studies of a traditional herbal
edicine for malaria and is unusual in including a major-
ty of children <5 years, who are the main target group
or malaria treatment (Willcox and Bodeker, 2004). In par-
icular, the current ‘improved traditional medicine’ on the
alian national formulary, ‘Malarial’, was not evaluated in
atients under the age of 5 years (Diallo et al., 2004).
lthough it is difﬁcult to compare results between trials
one with different populations and slightly different pro-
ocols, the reduction in parasitaemia at Day 14 appears to
e better with A. mexicana than with ‘Malarial’.
In several countries, Artemisia annua herbal tea has been
nvestigated as a local herbal treatment for malaria, but no
ublished trials of this have included children under the age
f 11 years. The latest trial showed a parasite clearance rate
f up to 77% at Day 7 (in patients aged ≥18 years), but only
8% of patients remained free of parasites at Day 28 (Mueller
t al., 2004). Unfortunately, clinical efﬁcacy criteria were
ot used. Whilst A. annua is without doubt a very promising
erbal antimalarial, it does not grow well in arid areas and
rials of its cultivation in Mali gave disappointing results.
n contrast, A. mexicana thrives in the arid Sahel climate,
aking it a very promising alternative in these areas.
Unlike newer antimalarials such as artemisinin combina-
ion therapies, the preparation used in this study did not
roduce complete clearance of parasites in most patients.
owever, in a setting where transmission is high, the rele-
ance of complete parasite clearance is debatable. A study
n Kampala, Uganda, suggested that asymptomatic para-
itaemia increases the risk of subsequent clinical malaria
Njama-Meya et al., 2004), but this ﬁnding was not repli-
ated in a study in Mali, where the epidemiology was
ore similar to that in our study (Bouvier et al., 1997).
ven when clearance is achieved, re-infection will occur
apidly (Yeka et al., 2005). Indeed, in Bandiagara (central
ali), treatment of asymptomatic carriers with sulfadox-
ne/pyrimethamine to clear parasites did not result in a
ecreased incidence of clinical malaria over the whole sea-
on, but in an incidence lower in the ﬁrst 4 weeks of
ollow-up, similar to the untreated group in Weeks 4—8,
hen more than double the untreated group in Weeks 9—12.
he infection-free interval may have attenuated naturally
cquired immunity (Coulibaly et al., 2002).
.4. Meaning of the study: possible explanations
nd implications for clinicians and policy-makersffectiveness depends not only on efﬁcacy but also on
ccess, cost and rational drug use. In the context of remote
reas where modern drugs are often lacking, unaffordable,
isused or counterfeit (Basco, 2004; Dossou-Yovo et al.,
t
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2001; Tumwesigire and Watson, 2002), it is entirely possible
that A. mexicana could prove effective at a programmatic
level. Further research is needed to test this hypothesis.
In remote villages such as the setting for this study, A.
mexicana is more accessible, more affordable and may be
associated with better compliance than any modern drugs,
including chloroquine. If further research conﬁrms its effec-
tiveness, A. mexicana could be proposed for malaria home
treatment programmes in areas with difﬁculties of access.
4.5. Unanswered questions and future research
It is important to see whether the preparation of A. mex-
icana can be modiﬁed to increase its efﬁcacy further. A
variety of preparations of this plant are used in the Sikasso
region of Mali (infusions, rawmacerations, decoctions where
the plant is boiled for only a few minutes). It is intended
to test these in vitro in order to attempt to produce an
improved formulation and to test other ways of adminis-
tration for small children.
Bibliographic data indicated the presence of the alkaloid
berberine, a well known antimalarial compound, in A. mexi-
cana. Chromatographic and densitometric methods allowed
us to measure approximately 20mg/l of berberine in the
village decoction (dosage conﬁrmed later by HPLC). This
amount of berberine is sufﬁcient to explain the high in vitro
activity displayed by A. mexicana extracts, but it is proba-
bly insufﬁcient to explain the observed therapeutic effect of
the decoction, since berberine is poorly absorbed orally. This
suggests the presence of other active compounds, whichmay
either act synergistically or enhance the oral bioavailability
of berberine. Further analyses are currently in progress to
address this question, not only because of potential phar-
macological interest, but also to provide a chemical marker
for quality control and selection in plant domestication.
Although there was no evidence of serious toxicity at
dose ‘B’ of the decoction, further toxicity tests will be
carried out on A. mexicana. QT prolongation was not specif-
ically assessed in the animal toxicity studies, but the lack
of lethality of even very high doses in the animal study
suggests that when taken alone the decoction is safe. Arge-
mone mexicana contains at least two alkaloids, protopine
and allocryptopine, which are known to prolong the refrac-
tory period of cardiac myocytes and could account for the
QT prolongation (McCawley, 1955). However, there were no
observed cases of symptomatic cardiac toxicity in this study
or in a subsequent larger study. There is a theoretical risk of
cardiac arrhythmia in cases of extreme QT interval prolonga-
tion. In practice this is unlikely to happen with A. mexicana
decoction alone, and it would only be a signiﬁcant risk if
patients were concurrently taking certain modern drugs that
also prolong the QT interval (for example halofantrine). In
remote villages, the use of modern drugs is unusual on a
long-term basis and it would be very unlikely that a patient
would take a modern drug at the same time as a herbal
medicine.5. Conclusion
Argemone mexicana decoction given twice daily for 7 days
resulted in signiﬁcantly more ACRs than a lower dose in the
D1197
reatment of uncomplicated falciparum malaria. It led to an
CR at Day 14 in 73% of all patients and in 89% of those aged
5 years. There were no serious side effects.
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